Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 August 2021Website:
http://renovorx.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 20 min agoDividend
Analysts recommendations
Institutional Ownership
RNXT Latest News
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.
RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents.
What type of business is RenovoRx?
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
What sector is RenovoRx in?
RenovoRx is in the Healthcare sector
What industry is RenovoRx in?
RenovoRx is in the Biotechnology industry
What country is RenovoRx from?
RenovoRx is headquartered in United States
When did RenovoRx go public?
RenovoRx initial public offering (IPO) was on 26 August 2021
What is RenovoRx website?
https://renovorx.com
Is RenovoRx in the S&P 500?
No, RenovoRx is not included in the S&P 500 index
Is RenovoRx in the NASDAQ 100?
No, RenovoRx is not included in the NASDAQ 100 index
Is RenovoRx in the Dow Jones?
No, RenovoRx is not included in the Dow Jones index
When was RenovoRx the previous earnings report?
No data
When does RenovoRx earnings report?
The next expected earnings date for RenovoRx is 14 November 2024